Clinical Data Gilead, Arcus tumble again in TIGIT, triggering 2 trial culls BioSpaceThe Phase 3 failure has prompted Gilead Sciences and Arcus Biosciences to terminate a mid-stage study of their TIGIT asset in lung cancer.Clinical DataOncologyRead full story pharminent April 21, 2026 (Last updated: April 21, 2026) BioSpace The Phase 3 failure has prompted Gilead Sciences and Arcus Biosciences to terminate a mid-stage study of their TIGIT asset in lung cancer. Clinical DataOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Jazz and Lilly cancer drugs cleared for use by NHSNext: MSD, Eisai report setback in first-line kidney cancer trial Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
